GLG News by Neurologists (US)

Copaxone has become the leading treatment for relapsing remitting MS in the US.  The results of the PRECISE trial will likely add to TEVA's sales momentum and boost sales further.

Lipitor is the only statin tested to reduce ischemic stroke. The new study also proved its role in reduce angina and MI

The potential side effect of liver damage of the new cholesterol agent from Merck will definitely slow or even halt the FDA approval of the medication.

LY450139 acts through decrease the production of amyloid beta, the protein found in some of AD pathology. This novel mechanism of action carries the hope of halting disease progression.

Statins are the lipid lowering agents that decrease the incidence of heart attacks and stroke. The other lipide lowering agents, no matter how good the ads. and drug representatives tell you, is unclear

In many respects, it is good that this trial was done.  For many years, retinal physicians had used Avastin injections preferentially over Lucentis for the treatment of AMD because of the vast difference in cost.

It is a common business practice for companies to wine and dine potential clients in an effort to secure new business contracts.  This is not considered to be a bribe, it is considered good business practice.  Is Stryker's case that different? Physicians go into practice for many reasons. ...

As the population age, more and more patients depend on medicare for their medical care. I do not know how they are going to afford the medication cost with bad economy and elevated drug price

R & D investment from pharmaceuticals has been the main source of research in the development of new treatment

Avaialbe treatments for diabetic neuropathy and other painful neuropathy are much improved over the last 10 years, but more effective ones are in great need